

Supplemental Table

Immune molecules and antimicrobial activity in cervicovaginal lavage in the five different groups: HPV-negative, low-risk, intermediate-risk, high-risk (other than HPV16) and HPV16

Variable (median [IQR])	HPV Negative (n = 32)	Low-risk HPV (n=33)	Intermediate-risk HPV (n=14)	High-risk HPV (n=41)	HPV16 (n=8)	p-value
^a Protein (log ₁₀ µg/mL) mean ± SD	2.32 ± 0.31	2.31 ± 0.28	2.39 ± 0.33	2.37 ± 0.37	2.45 ± 0.31	0.676
IL-1α (pg/mL)	64 [24.1- 116.1]	42.4 [21.2- 300.1]	89.2 [20.7- 426.7]	97.2 [36.3- 275]	195.7 [102.6- 1234.1]	0.111
^a IL-1β (log ₁₀ pg/mL)	0.45 ± 0.66	0.34 ± 0.67	0.59 ± 0.81	0.57 ± 0.82	0.85 ± 1.09	0.446
IL-1ra (pg/mL)	6822.3 [4398.1- 9588.4]	5591.6 [1905.7- 8959]	6170.7 [2042.2- 8676.9]	6446.0 [4516.6- 8319]	8644.1 [7414.1- 10000]	0.251
^b TNF, n (%)	16 (51.6%)	17 (54.8%)	5 (35.7%)	21 (52.5%)	7 (87.5%)	0.241
^b IL-6, n (%)	16 (51.6%)	17 (54.8%)	9 (64.3%)	27 (67.5%)	7 (87.5%)	0.333
^b IL-2, n (%)	3 (14.3%)	4 (15.4%)	2 (14.3%)	8 (27.6%)	1 (20%)	0.755
^b IL-17, n (%)	18 (64.3%)	19 (67.9%)	8 (57.1%)	19 (51.4%)	6 (75%)	0.603
^b IFN-α2, n (%)	0 (0%)	0 (0%)	0 (0%)	2 (6.9%)	0 (0%)	0.573
IFN-γ (pg/mL)	0.77 [0.32- 1.07]	0.51 [0.26- 1.28]	0.38 [0.13- 0.67]	0.71 [0.41- 1.63]	1.26 [0.53- 2.73]	0.119
^a IL-8 (log ₁₀ pg/mL)	2.43 ± 0.85	2.45 ± 0.72	2.51 ± 0.65	2.34 ± 0.75	2.91 ± 0.8	0.427
^b MIP-1α n (%)	21 (67.7%)	18 (58.1%)	6 (57.1%)	18 (45%)	4 (50%)	0.428
^b MIP-1β n (%)	11 (35.5%)	11 (35.5%)	2 (14.3%)	9 (22.5%)	2 (25%)	0.489
^b RANTES, n (%)	18 (58.1%)	15 (48.4%)	8 (57.1%)	20 (50%)	5 (62.5%)	0.904
IgA (ng/mL)	933 [347- 3234]	1874 [455- 3054]	1607 [411- 3136]	1421 [412- 4139]	3084.5 [503.5- 4126.5]	0.834
IgG (ng/mL)	9899 [4421- 22150]	6350 [2119- 13290]	7592 [2763- 23149]	11522 [4926- 19125]	9509 [5008.5- 41907]	0.538
Elafin (ng/mL)	100.1 [52-151.8]	97.7 [46.4- 238.6]	119.3 [9.8- 340.8]	43.9 [17.6- 190.7]	86.8 [54.6- 475.7]	0.544
Lactoferrin (ng/ml)	410 [152- 1123]	356 [50- 758]	447.2 [393- 687]	334.1 [50- 694.7]	1000.6 [145- 3385.1]	0.585
SLPI (pg/mL)	102950 [15225- 243259]	45583 [3750- 129463]	59808 [25646- 172065]	66402 [3750- 266049]	32120 [3750- 100875]	0.514
^a HNP1-3 (log ₁₀ pg/mL)	5.15 ± 0.49	4.98 ± 0.63	5.11 ± 0.52	4.86 ± 0.69	5.05 ± 0.85	0.373
HBD-1 (pg/mL)	434.3 [148.5- 2594]	594.3 [176.2- 2010.9]	392.6 [326.8- 538.4]	503 [210.5- 2317.9]	484.2 [253- 654.1]	0.948
HBD-2 (pg/mL)	349.2 [142- 758.8]	387.6 [89.1- 1610.5]	728.4 [269.6- 2457.9]	812.9 [145.5- 2349.1]	1794.0 [962.6- 6261.9]	0.117
^b HBD-3, n (%)	20 (62.5%)	21 (63.6%)	8 (66.7%)	27 (65.9%)	4 (50%)	0.942
E. coli inhibition (%)	22 [7- 34.5]	9 [1- 29]	14.5 [8- 68]	10 [-7- 31]	-4 [-19- 30.5]	0.119
HSV inhibition (%)	23 [8.7- 48]	20 [7- 34]	13.5 [-11- 33]	29 [2- 45]	18 [12- 26]	0.559
BaL inhibition (%)	57 [29- 91]	63.5 [34.5- 91]	59.5 [24.7- 78.5]	48 [9- 80.5]	-18.2 [-125.8- 57.2]	0.095
IIIb inhibition (%)	87 [64- 97]	91.5 [75.5- 99]	85.3 [37- 96]	84.7 [27- 96.7]	57.8 [22.3- 85]	0.041

^aCVL protein, IL-1β, IL-8, and HNP1-3 were log₁₀ transformed and are presented as mean ± SD.

^bCVL IL-6, IFN-α2, MIP-1α, MIP-1β, RANTES, IL-2, TNF, IL-17, and HBD-3 with > 25% of samples below the lower limit of detection (LLOD) were dichotomized at the LLOD and are presented as n(%) with detectable levels.